Impact of SC Daratumumab

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Key Takeaways

FDA approval of daratumumab and hyaluronidase-fihj with VRd offers new treatment options for transplant-eligible multiple myeloma patients, potentially improving outcomes.
The combination therapy's approval signifies a shift towards more comprehensive and effective treatment regimens in newly diagnosed multiple myeloma.
A pharmacy-led initiative indicates that post-injection observation for daratumumab may be unnecessary if the first dose is tolerated, streamlining patient monitoring.
These advancements could reduce healthcare resource burdens and enhance patient convenience, reflecting a move towards more efficient care practices.

Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

Now Viewing

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

Video content above is prompted by the following:

With the new FDA approval of daratumumab and hyaluronidase-fihj in combination with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma, how does this impact treatment within this patient population?
(Dr Adams) A recent pharmacy-led initiative showed that observation following subcutaneous administration of daratumumab may not be needed if the first injection is tolerated. How does this change patient monitoring procedures by the care team?